MINNEAPOLIS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024.
Inspire is scheduled to present at the Morgan Stanley conference at 7:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here.
Inspire is scheduled to present at the Wells Fargo conference at 3:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here.
Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-549-2443
| Last Trade: | US$92.56 |
| Daily Change: | 0.81 0.88 |
| Daily Volume: | 1,027,368 |
| Market Cap: | US$2.740B |
August 04, 2025 May 05, 2025 April 29, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
